These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33858992)

  • 1. Structure reveals the activation mechanism of the MC4 receptor to initiate satiation signaling.
    Israeli H; Degtjarik O; Fierro F; Chunilal V; Gill AK; Roth NJ; Botta J; Prabahar V; Peleg Y; Chan LF; Ben-Zvi D; McCormick PJ; Niv MY; Shalev-Benami M
    Science; 2021 May; 372(6544):808-814. PubMed ID: 33858992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into the Allosteric Mechanism of Setmelanotide (RM-493) as a Potent and First-in-Class Melanocortin-4 Receptor (MC4R) Agonist To Treat Rare Genetic Disorders of Obesity through an in Silico Approach.
    Falls BA; Zhang Y
    ACS Chem Neurosci; 2019 Mar; 10(3):1055-1065. PubMed ID: 30048591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural analysis of setmelanotide binding to MC4R variants in comparison to wild-type receptor.
    Hammad MM; Mohammad A; Alam-Eldin N; Madhu D; Al-Mulla F; Abu-Farha M; Abubaker J
    Life Sci; 2022 Oct; 307():120857. PubMed ID: 35931197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity.
    Nargund RP; Strack AM; Fong TM
    J Med Chem; 2006 Jul; 49(14):4035-43. PubMed ID: 16821763
    [No Abstract]   [Full Text] [Related]  

  • 5. Structures of active melanocortin-4 receptor-Gs-protein complexes with NDP-α-MSH and setmelanotide.
    Heyder NA; Kleinau G; Speck D; Schmidt A; Paisdzior S; Szczepek M; Bauer B; Koch A; Gallandi M; Kwiatkowski D; Bürger J; Mielke T; Beck-Sickinger AG; Hildebrand PW; Spahn CMT; Hilger D; Schacherl M; Biebermann H; Hilal T; Kühnen P; Kobilka BK; Scheerer P
    Cell Res; 2021 Nov; 31(11):1176-1189. PubMed ID: 34561620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MC4R Variants Modulate α-MSH and Setmelanotide Induced Cellular Signaling at Multiple Levels.
    Rodríguez Rondón AV; Welling MS; van den Akker ELT; van Rossum EFC; Boon EMJ; van Haelst MM; Delhanty PJD; Visser JA
    J Clin Endocrinol Metab; 2024 Sep; 109(10):2452-2466. PubMed ID: 38567654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.
    Collet TH; Dubern B; Mokrosinski J; Connors H; Keogh JM; Mendes de Oliveira E; Henning E; Poitou-Bernert C; Oppert JM; Tounian P; Marchelli F; Alili R; Le Beyec J; Pépin D; Lacorte JM; Gottesdiener A; Bounds R; Sharma S; Folster C; Henderson B; O'Rahilly S; Stoner E; Gottesdiener K; Panaro BL; Cone RD; Clément K; Farooqi IS; Van der Ploeg LHT
    Mol Metab; 2017 Oct; 6(10):1321-1329. PubMed ID: 29031731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural Complexity and Plasticity of Signaling Regulation at the Melanocortin-4 Receptor.
    Kleinau G; Heyder NA; Tao YX; Scheerer P
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32785054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment.
    Ayers KL; Glicksberg BS; Garfield AS; Longerich S; White JA; Yang P; Du L; Chittenden TW; Gulcher JR; Roy S; Fiedorek F; Gottesdiener K; Cohen S; North KE; Schadt EE; Li SD; Chen R; Van der Ploeg LHT
    J Clin Endocrinol Metab; 2018 Jul; 103(7):2601-2612. PubMed ID: 29726959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure elucidation of a human melanocortin-4 receptor specific orthosteric nanobody agonist.
    Fontaine T; Busch A; Laeremans T; De Cesco S; Liang YL; Jaakola VP; Sands Z; Triest S; Masiulis S; Dekeyzer L; Samyn N; Loeys N; Perneel L; Debaere M; Martini M; Vantieghem C; Virmani R; Skieterska K; Staelens S; Barroco R; Van Roy M; Menet C
    Nat Commun; 2024 Oct; 15(1):7029. PubMed ID: 39353917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Setmelanotide: First Approval.
    Markham A
    Drugs; 2021 Feb; 81(3):397-403. PubMed ID: 33638809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanocortin pathways: suppressed and stimulated melanocortin-4 receptor (MC4R).
    Hainer V; Aldhoon Hainerová I; Kunešová M; Taxová Braunerová R; Zamrazilová H; Bendlová B
    Physiol Res; 2020 Sep; 69(Suppl 2):S245-S254. PubMed ID: 33094623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanocortin-4 Receptor Signalling: Importance for Weight Regulation and Obesity Treatment.
    Kühnen P; Krude H; Biebermann H
    Trends Mol Med; 2019 Feb; 25(2):136-148. PubMed ID: 30642682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological chaperones restore function to MC4R mutants responsible for severe early-onset obesity.
    René P; Le Gouill C; Pogozheva ID; Lee G; Mosberg HI; Farooqi IS; Valenzano KJ; Bouvier M
    J Pharmacol Exp Ther; 2010 Dec; 335(3):520-32. PubMed ID: 20826565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Setmelanotide-like Effect at MC4R Is Achieved by MC4R Dimer Separation.
    Reininghaus N; Paisdzior S; Höpfner F; Jyrch S; Cetindag C; Scheerer P; Kühnen P; Biebermann H
    Biomolecules; 2022 Aug; 12(8):. PubMed ID: 36009013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The melanocortin pathway and energy homeostasis: From discovery to obesity therapy.
    Yeo GSH; Chao DHM; Siegert AM; Koerperich ZM; Ericson MD; Simonds SE; Larson CM; Luquet S; Clarke I; Sharma S; Clément K; Cowley MA; Haskell-Luevano C; Van Der Ploeg L; Adan RAH
    Mol Metab; 2021 Jun; 48():101206. PubMed ID: 33684608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exposure of MC4R to agonist in the endoplasmic reticulum stabilizes an active conformation of the receptor that does not desensitize.
    Granell S; Molden BM; Baldini G
    Proc Natl Acad Sci U S A; 2013 Dec; 110(49):E4733-42. PubMed ID: 24248383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological chaperone action in humanized mouse models of MC4R-linked obesity.
    René P; Lanfray D; Richard D; Bouvier M
    JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans.
    Srinivasan S; Lubrano-Berthelier C; Govaerts C; Picard F; Santiago P; Conklin BR; Vaisse C
    J Clin Invest; 2004 Oct; 114(8):1158-64. PubMed ID: 15489963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The MC4 receptor and control of appetite.
    Adan RA; Tiesjema B; Hillebrand JJ; la Fleur SE; Kas MJ; de Krom M
    Br J Pharmacol; 2006 Dec; 149(7):815-27. PubMed ID: 17043670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.